{"filing":{"accession_number":"0001213900-26-090491","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"ea0302340-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026090491/ea0302340-6k_radiopharm.htm"},"events":[{"id":28100,"run_id":25683,"accession_number":"0001213900-26-090491","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This announcement discloses a scheduled End-of-Phase 2 meeting with the U.S. FDA for RAD 101, a pivotal clinical development milestone. The company reports positive Phase 2b trial results (93% concordance with MRI) and confirms it remains on track to be Phase 3-ready by year-end 2026. This is a material operational/regulatory milestone for a clinical-stage biopharmaceutical company advancing a lead candidate toward pivotal trials, but it does not fit the specific event types (e.g., it is not an earnings release, executive change, M\u0026A activity, or material impairment). The disclosure would affect a reasonable investor's assessment of the company's clinical development progress and regulatory pathway.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-17","form":"6-K","submitted_at":null,"items":[{"id":29905,"accession_number":"0001213900-26-090491","item_number":"EX-99.1","item_title":"ea030234001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses a scheduled End-of-Phase 2 meeting with the U.S. FDA for RAD 101, a pivotal clinical development milestone. The company reports positive Phase 2b trial results (93% concordance with MRI) and confirms it remains on track to be Phase 3-ready by year-end 2026. This is a material operational/regulatory milestone for a clinical-stage biopharmaceutical company advancing a lead candidate toward pivotal trials, but it does not fit the specific event types (e.g., it is not an earnings release, executive change, M\u0026A activity, or material impairment). The disclosure would affect a reasonable investor's assessment of the company's clinical development progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:01:43.624275+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29905,"accession_number":"0001213900-26-090491","item_number":"EX-99.1","item_title":"ea030234001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses a scheduled End-of-Phase 2 meeting with the U.S. FDA for RAD 101, a pivotal clinical development milestone. The company reports positive Phase 2b trial results (93% concordance with MRI) and confirms it remains on track to be Phase 3-ready by year-end 2026. This is a material operational/regulatory milestone for a clinical-stage biopharmaceutical company advancing a lead candidate toward pivotal trials, but it does not fit the specific event types (e.g., it is not an earnings release, executive change, M\u0026A activity, or material impairment). The disclosure would affect a reasonable investor's assessment of the company's clinical development progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:01:43.624275+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-17"}]}